CROSSJECT (EPA:ALCJ) | WebDisclosure

Basculer en Français

8600	Companies
140510	Keywords
76478	Articles
75073	Press releases

Home
Companies
CROSSJECT

BRIEF

published on 03/27/2025 at 07:35, 11 days ago

CROSSJECT publie ses résultats financiers 2024

Résultats Financiers Partenariats Situation De Trésorerie ZEPIZURE® Dépôt Auprès De La FDA
BRIEF

published on 03/27/2025 at 07:35, 11 days ago

CROSSJECT Publishes 2024 Financial Results

Financial Results Cash Position Partnerships FDA Filing ZEPIZURE®
PRESS RELEASE

published on 03/27/2025 at 07:30, 11 days ago

CROSSJECT reports financial results for 2024
CROSSJECT reports financial results for 2024 and progress in clinical and regulatory activities, recruitment of COO, and increased cash position. Key achievements and future plans outlined

Financial Results Cash Position Clinical Activities Crossject Regulatory Development
BRIEF

published on 03/25/2025 at 07:35, 13 days ago

Partenariat stratégique entre CROSSJECT et ETON PHARMACEUTICALS

Eton Pharmaceuticals Crossject ZENEO® Hydrocortisone Insuffisance Surrénale
BRIEF

published on 03/25/2025 at 07:35, 13 days ago

Strategic partnership between CROSSJECT and ETON PHARMACEUTICALS

Eton Pharmaceuticals Crossject ZENEO® Hydrocortisone Adrenal Insufficiency
PRESS RELEASE

published on 03/25/2025 at 07:30, 13 days ago

CROSSJECT fait le point sur sa collaboration avec ETON PHARMACEUTICALS, Inc. et sur le programme ZENEO® Hydrocortisone dans le domaine de l'insuffisance surrénale
CROSSJECT renforce sa collaboration avec ETON PHARMACEUTICALS pour le programme ZENEO® Hydrocortisone dans l'insuffisance surrénale, avec des depôts de dossiers prévus à partir de S2 2026

Collaboration Eton Pharmaceuticals Crossject Insuffisance Surrénale ZENEO® Hydrocortisone
PRESS RELEASE

published on 03/25/2025 at 07:30, 13 days ago

CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
CROSSJECT enhances collaboration with ETON PHARMACEUTICALS Inc. on ZENEO adrenal insufficiency program, introducing new hydrocortisone formulation for the hospital market

Eton Pharmaceuticals Crossject Hydrocortisone Adrenal Insufficiency ZENEO
BRIEF

published on 03/10/2025 at 14:22, 27 days 17 hours ago

Crossject: Update on voting rights and shares as of January 31, 2025

Share Capital Voting Rights Actions Pharmaceutical Crossject
BRIEF

published on 03/10/2025 at 14:22, 27 days 17 hours ago

Crossject : Mise à jour sur les droits de vote et actions au 31 janvier 2025

Droits De Vote Capital Social Actions Pharmaceutique Crossject
PRESS RELEASE

published on 03/10/2025 at 14:17, 27 days 17 hours ago

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
Crossject communique le nombre total de droits de vote et d’actions composant son capital social au 31 janvier 2025, conformément aux règlements de l’AMF et du Code de commerce

Droits De Vote Capital Social Pharmaceutique Communiqué Crossject

1 2 ... 7

Accesswire

Published on 04/07/2025 at 00:05, 7 hours 33 minutes ago

Sea Pharmaceuticals Announces Strategic Relationship to Advance Treatments For Patients with CNS Disorders
Published on 04/05/2025 at 05:50, 2 days 1 hour ago

Lobe Sciences Provides Corporate Update
Published on 04/05/2025 at 01:50, 2 days 5 hours ago

Battery X Metals Achieves Graphite Recovery Breakthrough in Partnership with Global Top 20 University in Controlled Trials
Published on 04/05/2025 at 01:00, 2 days 6 hours ago

AIML Announces Proposed Private Placement
Published on 04/05/2025 at 00:15, 2 days 7 hours ago

UniDoc Announces LIFE Offering

View all ACCESSWIRE

EQS Group

Published on 04/07/2025 at 07:03, 34 minutes ago

Swiss Re to be appointed as co-investment manager of GAM's catastrophe bond and ILS fund range
Published on 04/07/2025 at 07:00, 37 minutes ago

Julius Baer further streamlines its organisation to reinforce focus on clients and sustainable growth
Published on 04/06/2025 at 18:20, 13 hours 17 minutes ago

EQS-Adhoc: QIAGEN N.V.: QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook
Published on 04/06/2025 at 15:09, 16 hours 28 minutes ago

EQS-Adhoc: DEUTZ acquires developer of electrification solutions UMS
Published on 04/04/2025 at 19:00, 2 days 12 hours ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF

Les Echos

Published on 04/07/2025 at 07:01, 37 minutes ago

bioMérieux obtient le marquage CE pour LUMED™ APSS™, une solution logicielle de pointe pour aider à prendre des décisions en matière de bon usage des antibiotiques
Published on 04/07/2025 at 07:01, 37 minutes ago

bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solution to aid medical decision-making in Antimicrobial Stewardship
Published on 04/04/2025 at 19:18, 2 days 12 hours ago

Mersen: Number of shares and voting rights as of March 31, 2025
Published on 04/04/2025 at 19:18, 2 days 12 hours ago

Mersen : nombre d'actions et de droits de vote au 31 mars 2025
Published on 04/04/2025 at 18:17, 2 days 13 hours ago

Reporting on share buyback transactions carried out between March 31 and April 3, 2025

View all LES ECHOS COMFI WIRE